It doesn't need to do much, it is the sum of all parts that will propel the stock in the future.
With negotiations underway the DoD grant followed by Orphan Status and now Fast track it bodes very well from a bargaining position.
The FDA are one of the most time consuming/wasting entities when comes to granted trial approval so it is a big deal in that regard.
Also the last two approvals seem to show clearly that the FDA is on board with Tapimmune and it's direction and products.
It's like a puzzle we have another positive/relevant piece in place each individual piece, may not by itself be game changing but the sum of all parts is starting to show a clear and relevant story.
Very good news for the bargaining position they are involved in at the moment.